Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price rose 37.9% during mid-day trading on Friday . The stock traded as high as C$0.24 and last traded at C$0.20. Approximately 1,160,600 shares were traded during mid-day trading, an increase of 120% from the average daily volume of 528,233 shares. The stock had previously closed at C$0.15.
Hemostemix Price Performance
The company has a fifty day simple moving average of C$0.09 and a 200-day simple moving average of C$0.07. The company has a market cap of C$17.42 million, a P/E ratio of -10.00 and a beta of 0.20.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
See Also
- Five stocks we like better than Hemostemix
- What is a Stock Market Index and How Do You Use Them?
- Zymeworks in Focus for Insider Activity: Catalysts Ahead
- Are Penny Stocks a Good Fit for Your Portfolio?
- Kura Sushi Stock Dips Into a Hot Buying Opportunity
- How to Plot Fibonacci Price Inflection Levels
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
-FWOG.png?v=2024-12-29&h=45&w=95&zc=2){kind=small}